GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Advanced Oncotherapy PLC (FRA:R3I1) » Definitions » Tax Expense

Advanced Oncotherapy (FRA:R3I1) Tax Expense : €-0.09 Mil (TTM As of Jun. 2022)


View and export this data going back to 2018. Start your Free Trial

What is Advanced Oncotherapy Tax Expense?

Advanced Oncotherapy's tax expense for the months ended in Jun. 2022 was €-0.09 Mil. Its tax expense for the trailing twelve months (TTM) ended in Jun. 2022 was €-0.09 Mil.


Advanced Oncotherapy Tax Expense Historical Data

The historical data trend for Advanced Oncotherapy's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advanced Oncotherapy Tax Expense Chart

Advanced Oncotherapy Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Tax Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.20 -0.85 -1.28 - -

Advanced Oncotherapy Semi-Annual Data
Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -0.09

Advanced Oncotherapy Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Jun. 2022 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.09 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Advanced Oncotherapy  (FRA:R3I1) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Advanced Oncotherapy Tax Expense Related Terms

Thank you for viewing the detailed overview of Advanced Oncotherapy's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Advanced Oncotherapy (FRA:R3I1) Business Description

Traded in Other Exchanges
N/A
Address
4 Tenterden Street, Third Floor, London, GBR, W1S 1TE
Advanced Oncotherapy PLC is active in the healthcare domain in the United Kingdom. As a medical care provider, its focus is to develop technologies to maximize the destructive effect of radiation on tumors whilst minimizing damage to healthy tissues. It develops an affordable proton-based radiotherapy system, using innovative and clinically effective technology, thereby contributing to curing critical unmet conditions. The company's only business segment is Proton Therapy.

Advanced Oncotherapy (FRA:R3I1) Headlines

No Headlines